Some synergistic effects of anticancer drugs combined with ATRA in non-APL AML
| Type of drug . | Drug target . | Tested models . | Combined effect with ATRA . | Reference . |
|---|---|---|---|---|
| DNA hypomethylating agents | DNMT | High-risk AML patient | Complete clinical remissions with ATRA+decitabine | 63, 101 |
| Histone modifiers | Histone demethylase (LSD-1/KDM-1A) | AML cell lines | Enhanced AML cell differentiation | 71, 73-75 |
| Histone acetyltransferase(GCN-5) | AML cell lines | Enhanced cell differentiation | 124 | |
| SUMOylation inhibitors | SUMOylation enzymes (E1, E2) | AML cell lines Mouse xenografts | Increased ATRA-induced differentiation | 81 |
| Kinase inhibitors | FLT3-ITD | AML cell lines | Increased apoptosis of leukemia cells and survival in mice | 19 |
| HER-2 | Mouse xenografts AML cell lines | Promotion of AML cell differentiation | 18 | |
| ATRA metabolism | CYP26 | AML cell lines | Inhibited stromal CYP26 favoring ATRA-induced differentiation | 125 |
| Type of drug . | Drug target . | Tested models . | Combined effect with ATRA . | Reference . |
|---|---|---|---|---|
| DNA hypomethylating agents | DNMT | High-risk AML patient | Complete clinical remissions with ATRA+decitabine | 63, 101 |
| Histone modifiers | Histone demethylase (LSD-1/KDM-1A) | AML cell lines | Enhanced AML cell differentiation | 71, 73-75 |
| Histone acetyltransferase(GCN-5) | AML cell lines | Enhanced cell differentiation | 124 | |
| SUMOylation inhibitors | SUMOylation enzymes (E1, E2) | AML cell lines Mouse xenografts | Increased ATRA-induced differentiation | 81 |
| Kinase inhibitors | FLT3-ITD | AML cell lines | Increased apoptosis of leukemia cells and survival in mice | 19 |
| HER-2 | Mouse xenografts AML cell lines | Promotion of AML cell differentiation | 18 | |
| ATRA metabolism | CYP26 | AML cell lines | Inhibited stromal CYP26 favoring ATRA-induced differentiation | 125 |